低级别胶质瘤质子放疗的认知功能、生活质量与生存结局:一项II期研究
该单中心前瞻性II期试验纳入60例WHO 1-2级或IDH突变型3级胶质瘤患者,接受54 Gy(RBE)或59.4 Gy(RBE)质子治疗。中位随访7.0年,5年PFS和OS分别为79.1%和85.6%,5年新发神经认知缺陷26%,神经内分泌功能障碍5.3%,无晚期3级毒性。
要点
- 质子治疗低级别胶质瘤5年PFS 79.1%、OS 85.6%,IDH突变伴1p/19q共缺失者PFS最高(100%)。
- 5年新发神经认知缺陷26%,神经内分泌功能障碍5.3%,仅1例归因于放疗。
- 生活质量6个月时短暂下降,5年时15%出现有临床意义的下降;无晚期3级毒性,1例4级放射性坏死。
核心结论
- 质子治疗低级别胶质瘤可实现有效疾病控制且长期毒性有限,支持其作为标准放疗模式,并需与光子 therapy 开展对比试验。
研究设计与样本
- 单中心前瞻性II期试验,纳入60例WHO 1-2级胶质瘤或IDH突变型3级胶质瘤患者。
- 质子治疗按肿瘤分级给予54 Gy(RBE)或59.4 Gy(RBE)。
- 主要终点为无进展生存期(PFS),次要终点包括总生存期(OS)、神经认知与神经内分泌功能及生活质量(QOL)。
主要发现
- 中位随访7.0年,5年PFS为79.1%,5年OS为85.6%。
- PFS在IDH突变伴1p/19q共缺失胶质瘤中最高(100%),在IDH野生型肿瘤中最低(62.5%)。
- 5年时26%患者出现新发神经认知缺陷。
- 神经内分泌功能障碍发生率为5.3%,仅1例归因于放疗。
- 生活质量在6个月时短暂下降,5年时15%出现有临床意义的下降;无晚期3级毒性,发生1例4级放射性坏死。
关键数值与推荐
- 质子治疗剂量按肿瘤分级为54 Gy(RBE)或59.4 Gy(RBE)。
- 神经认知测试在基线和每两年进行;生活质量采用FACT-Brain问卷评估;毒性按CTCAE v4.0分级。
临床怎么用
- 对于低级别胶质瘤,质子治疗可作为有效且长期毒性有限的放疗选择。
- 治疗决策中需关注IDH野生型患者PFS较低(62.5%)及5年神经认知缺陷风险(26%)。
- 需监测生活质量短暂下降及罕见但严重的放射性坏死(1例4级)。
局限性
- 单中心、单臂II期设计,样本量60例,缺乏与光子放疗的对照比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lower grade gliomas (LGGs) typically affect younger adults and are associated with long-term survival. Treatment-related toxicities, especially neurocognitive and neuroendocrine effects, are a concern. Proton therapy may reduce these risks by minimizing radiation exposure to healthy brain tissue. This study evaluates the safety and efficacy of proton therapy in LGG patients, focusing on neurocognitive, neuroendocrine, and quality-of-life (QOL) outcomes. METHODS: This single-institution, prospective phase 2 trial enrolled 60 patients with WHO grade 1-2 gliomas or IDH-mutant grade 3 gliomas. Proton therapy was delivered at 54 Gy(RBE) or 59.4 Gy(RBE) by tumor grade. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), neurocognitive and neuroendocrine function, and QOL. Neurocognitive testing occurred at baseline and biennially. Quality-of-life was assessed using the FACT-Brain questionnaire. Toxicities were graded per CTCAE v4.0. RESULTS: With a median follow-up of 7.0 years, 5-year PFS and OS were 79.1% and 85.6%, respectively. Progression-free survival was highest in IDH-mutant, 1p/19q co-deleted gliomas (100%) and lowest in IDH-wildtype tumors (62.5%). New neurocognitive deficits occurred in 26% of patients at 5 years. Neuroendocrine dysfunction occurred in 5.3%, with only one case attributed to radiation. Quality-of-life declined transiently at 6 months, with 15% showing a clinically meaningful decline at 5 years. No late grade 3 toxicities were observed; one case of grade 4 radionecrosis occurred. CONCLUSIONS: Proton therapy for LGG can offer effective disease control with modest long-term toxicity. These findings support its use as a standard radiation modality and highlight the need for comparative trials with photon therapy.
引用
- Slater JM, Horick NK, Nachtigall LB, et al. Cognitive function, quality of life, and survival outcomes in patients with lower grade gliomas treated with proton radiation therapy: A phase II study. Neuro Oncol. 2026. PMID: 41581137. doi:10.1093/neuonc/noag008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。